EX-99.1 2 ex99_1.htm PRESS RELEASE DATED MAY 6, 2020
Exhibit 99.1


FOR IMMEDIATE RELEASE

NU SKIN ENTERPRISES REPORTS FIRST-QUARTER 2020 RESULTS

PROVO, Utah — May 6, 2020 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first-quarter 2020 results above guidance.

Executive Summary
Q1 2020 vs. Prior-Year Quarter

Revenue:
  
$ 518.0 million; (17%)
•     (2%) fx impact or ($14.3) million
Earnings Per Share (EPS):
  
$0.36; (53%)
Sales Leaders:
  
49,551; (22%)
Customers:
  
1,130,947; (5%)

“The efforts and resiliency of our sales leaders and global teams helped us achieve revenue and earnings above guidance in the first quarter,” said Ritch Wood, chief executive officer. “While COVID-19 continues to present significant challenges globally, we are grateful for the heroic efforts of healthcare workers, first responders and other essential workers around the world. From a Nu Skin perspective, our entire organization has mobilized to protect the health and safety of our teams and ensure business continuity for our customers. As a result, we have been able to maintain support for our sales leaders, leverage our supply chain to meet consumer demand for our products and utilize technology to facilitate remote work for both our sales leaders and employees.”

“Our first quarter results demonstrated continued stability in the Nu Skin business with strong customer activity. More than 80 percent of our revenue comes through our digital properties which have been enhanced by our strategic investments in technology infrastructure and digital tools. Additionally, our manufacturing and supply chain investments have enabled us to effectively manage inventory and fulfill customer orders worldwide through very challenging circumstances. Our manufacturing segment performed well considering the supply chain disruptions related to certain ingredients and packaging materials due to the pandemic. We generated solid cash flow during the quarter, increased our dividend for the 19th consecutive year and utilized our cash to repurchase shares in a way that we believe will benefit shareholders going forward,” continued Wood.

Q1 2020 Year-Over-Year Operating Results

Revenue:
  
$518.0 million compared to $623.6 million
•      (2%) fx impact or ($14.3) million
Gross Margin:
  
75.7% compared to 76.5%
•      Nu Skin business was 78.1% compared to 78.7%
Selling Expenses:
  
39.8% of revenue compared to 40.0%
•      Nu Skin business was 42.0% compared to 42.0%
G&A Expenses:
  
28.9% of revenue compared to 25.4%
Operating Margin:
  
7.1% compared to 11.0%
Other Income / (Expense):
  
($6.2) million compared to ($2.8) million
•      ($3.1) million due to fx
Income Tax Rate:
  
35.1% compared to 34.7%
EPS:
  
$0.36 compared to $0.77

Stockholder Value

Dividend Payments:
  
$20.7 million
Stock Repurchases:
  
$60.9 million
•      $409.3 million remaining in authorization

Q2 and Full-Year 2020 Outlook

Q2 2020 Revenue:
  
$520 to $550 million; (12 to 17%)
•      Approximately (3 to 4%) fx impact
Q2 2020 EPS:
  
$0.42 to $0.52
2020 Revenue:
  
$2.17 billion to $2.26 billion; (7 to 10%)
•      Approximately (2 to 3%) fx impact
2020 EPS
  
$2.05 to $2.35

“While there is a great deal of uncertainty in the broader economy, we are optimistic our business will perform well as sales leaders leverage our technology investments to drive product demand and interest in the business opportunity,” said Wood. “The situation in Mainland China is stabilizing with the country returning to work, a key development we believe will translate into improvement throughout the year. We anticipate similar trends in most of our other markets as pandemic restrictions begin to ease elsewhere across the globe. We continue to believe this trend, paired with the global preview of our newest beauty device late in 2020, sets our business up for a return to growth toward the end of the year,” Wood concluded.

Mark Lawrence, chief financial officer, added, “We are encouraged with our first-quarter results, despite the economic challenges. During the quarter, we generated strong cash from operations and leveraged the strength of our balance sheet to pay an increased dividend and repurchase $61 million of our stock. As we look ahead to the second quarter, our revenue guidance is $520 to $550 million, which includes an approximate 3 to 4 percent unfavorable foreign currency impact, and an earnings per share outlook of $0.42 to $0.52. Our 2020 revenue guidance of $2.17 to $2.26 billion reflects a negative foreign currency impact of 2 to 3 percent, an increased fx headwind of more than 1 percent from our previous guidance, and we anticipate annual earnings per share of $2.05 to $2.35.”

Conference Call
The Nu Skin management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available at the same URL through May 20, 2020.

About Nu Skin Enterprises, Inc.
Founded 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies and life-improving values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskinenterprises.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, product launches, benefits to shareholders, strategies and initiatives; statements of management’s expectations regarding the future status of the COVID-19 pandemic globally and across the company’s markets, and government and public behavior in response to such status; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “continue,” “anticipate,” “optimistic,” “benefit,” “project,” “outlook,” “guidance,” “plan,” “continue,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 •
risk that epidemics, including the recent outbreak of coronavirus, and other crises could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;

•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
uncertainty regarding the continued impact of the 100-day review and negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;

•
unpredictable economic conditions and events globally, including trade policies and tariffs;

•
uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

•
continued competitive pressures in the company’s markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission, including the Form 10-K for the fiscal year ending December 31, 2019, the Forms 8-K filed on March 18, 2020 and April 21, 2020, and the Form 10-Q for the fiscal quarter ending March 31, 2020. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

The Company’s revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).

   
Three Months Ended
March 31,
          
Constant-
Currency
  
   
2020
    
2019
    
Change
    
Change
  
                         
Nu Skin
                        
Mainland China
  
$
137,696
    
$
208,488
      
(34
)%
    
(31
)%
South Korea
    
75,719
      
83,853
      
(10
)%
    
(4
)%
Americas/Pacific
    
74,573
      
86,456
      
(14
)%
    
(9
)%
Southeast Asia
    
69,586
      
72,495
      
(4
)%
    
(3
)%
Japan
    
61,300
      
62,109
      
(1
)%
    
(2
)%
Hong Kong/Taiwan
    
35,827
      
40,558
      
(12
)%
    
(13
)%
EMEA
    
35,403
      
41,818
      
(15
)%
    
(13
)%
Other
    
773
      
(1,426
)
    
154
%
    
154
%
Total Nu Skin
    
490,877
      
594,351
      
(17
)%
    
(15
)%
Manufacturing
    
27,147
      
29,272
      
(7
)%
    
(7
)%
Grow Tech
    
4
      
—
      
—
      
—
  
Total
  
$
518,028
    
$
623,623
      
(17
)%
    
(15
)%

The company’s Customers and Sales Leaders statistics by segment for the three-month periods ended March 31 are presented in the following table.

   
As of
March 31, 2020
    
As of
March 31, 2019
    
% Increase (Decrease)
  
   
Customers
    
Sales Leaders
    
Customers
    
Sales Leaders
    
Customers
    
Sales Leaders
  
                                     
Mainland China
    
271,536
      
16,159
      
272,053
      
26,986
      
—
      
(40
)%
South Korea
    
174,004
      
6,608
      
181,150
      
6,671
      
(4
)%
    
(1
)%
Americas/Pacific
    
214,139
      
6,930
      
242,925
      
7,862
      
(12
)%
    
(12
)%
Southeast Asia
    
145,116
      
6,634
      
138,112
      
7,071
      
5
%
    
(6
)%
Japan
    
119,784
      
5,635
      
126,526
      
5,840
      
(5
)%
    
(4
)%
Hong Kong/Taiwan
    
66,024
      
3,348
      
70,354
      
3,959
      
(6
)%
    
(15
)%
EMEA
    
140,344
      
4,237
      
162,086
      
4,859
      
(13
)%
    
(13
)%
                                                 
Total
    
1,130,947
      
49,551
      
1,193,206
      
63,248
      
(5
)%
    
(22
)%

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
March 31,
  
   
2020
    
2019
  
             
Revenue
  
$
518,028
    
$
623,623
  
Cost of sales
    
125,793
      
146,664
  
Gross profit
    
392,235
      
476,959
  
                 
Operating expenses:
                
Selling expenses
    
206,042
      
249,708
  
General and administrative expenses
    
149,628
      
158,598
  
Total operating expenses
    
355,670
      
408,306
  
                 
Operating income
    
36,565
      
68,653
  
Other income (expense), net
    
(6,174
)
    
(2,848
)
                 
Income before provision for income taxes
    
30,391
      
65,805
  
Provision for income taxes
    
10,661
      
22,803
  
                 
Net income
  
$
19,730
    
$
43,002
  
                 
Net income per share:
                
Basic
  
$
0.36
    
$
0.78
  
Diluted
  
$
0.36
    
$
0.77
  
                 
Weighted-average common shares outstanding (000s):
                
Basic
    
55,059
      
55,436
  
Diluted
    
55,101
      
56,128
  

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
March 31,
2020
    
December 31,
2019
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
352,578
    
$
335,630
  
Current investments
    
9,087
      
8,413
  
Accounts receivable
    
43,973
      
50,378
  
Inventories, net
    
257,474
      
275,891
  
Prepaid expenses and other
    
66,457
      
69,854
  
Total current assets
    
729,569
      
740,166
  
                 
Property and equipment, net
    
449,486
      
453,604
  
Right-of-use assets
    
147,678
      
144,326
  
Goodwill
    
196,573
      
196,573
  
Other intangible assets, net
    
77,796
      
80,321
  
Other assets
    
145,217
      
154,016
  
Total assets
  
$
1,746,319
    
$
1,769,006
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
39,891
    
$
38,979
  
Accrued expenses
    
285,213
      
290,281
  
Current portion of long-term debt
    
95,000
      
27,500
  
Total current liabilities
    
420,104
      
356,760
  
                 
Operating lease liabilities
    
108,145
      
105,701
  
Long-term debt
    
327,197
      
334,461
  
Other liabilities
    
90,375
      
96,795
  
Total liabilities
    
945,821
      
893,717
  
                 
Stockholders’ equity:
                
Class A common stock
    
91
      
91
  
Additional paid-in capital
    
557,916
      
557,544
  
Treasury stock, at cost
    
(1,384,036
)
    
(1,324,826
)
Accumulated other comprehensive loss
    
(100,289
)
    
(85,292
)
Retained earnings
    
1,726,816
      
1,727,772
  
Total stockholders' equity
    
800,498
      
875,289
  
Total liabilities and stockholders’ equity
  
$
1,746,319
    
$
1,769,006
  

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577